On May 7, 2021, Acasti Pharma announced the entering into of a definitive agreement to acquire Grace Therapeutics, a biopharmaceutical company that develops innovative drug delivery technologies for rare and orphan diseases. Upon completion of the acquisition, Acasti will acquire Grace’s pipeline of drug candidates addressing critical unfulfilled medical needs, and the potential to deliver significant value to patients and providers.
Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using omega-3 fatty acids.
Osler, Hoskin & Harcourt LLP advised Acasti Pharma with a team consisting of François Paradis, Jason Comerford and Matthew Oliver (Corporate), Paul Seraganian, Manon Thivierge and Kaleigh Hawkins-Schulz (Taxation).